Home
Heart Failure

Heart Failure

Hypertrophic Cardiomyopathy in Review: ESC–HFA 2022 & How to Differentiate HCM From Its Phenocopies

Ahmad Masri

0.50 AMA PRA Credit

Published: 03/08/2022

Recall the efficacy and safety of existing HCM treatments and summarise results from ongoing trials with experimental treatments
Differentiate the signs and symptoms of HCM from other conditions that frequently mask, or mimic the disease and in the presence of comorbidities

Making Gains in HFpEF: An Appraisal of Where We Are Now

Shelley Zieroth Javed Butler Carolyn Lam

Published: 08/07/2022

Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
Recall current inertia rates amongst prescribers who manage heart failure
Adopt effective treatment strategies for HFpEF patients early in the disease course
Recall current guideline directed medical therapy options in HFpEF
Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF

Hypertrophic Cardiomyopathy in Review: Highlights of ACC 2022

Milind Y Desai

0.25 AMA PRA Credit

Published: 21/06/2022

Recall the efficacy and safety of existing HCM treatments and summarise results from ongoing trials with experimental treatments

Heart Failure Management in a Changing Paradigm

1 EBAC

Published: 16/06/2022

Recall the utility of EF in heart failure treatment, patient selection and treatment response
Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
InIncorporate quality of life measures for assessing therapeutic efficacy in HF
Recall outcomes from heart failure trials from recent congress and publications and their impact on practice

The 2022 ACC Heart Failure Guidelines: What Do They Mean for Your Practice?

Published: 09/06/2022

Summarise the main updates to the 2022 ACC heart failure (HF) guidelines
Compare updates from the ACC with the 2021 ESC HF guidelines
Recall guideline recommendations for the initiation of foundational therapy for heart failure
Adopt foundational GMDT early in the disease course
Postulate how ejection fraction will be used in future trials and in future guidelines
Review existing and forthcoming trial evidence on SGLT-2 inhibitors in HFpEF

Hypertrophic Cardiomyopathy: Application of Emerging Data and Genetic Testing in Clinical Practice

Carolyn Ho

0.75 AMA PRA Credit

Published: 17/02/2022

Recall the efficacy and safety of existing HCM treatments
Summarise results from ongoing trials with experimental treatments
Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening

Heart Failure

A Review of Emerging ARNI Data in HFrEF

Andrew Coats Scott Solomon Uwe Zeymer

1.00 EBAC

Published: 31/10/2019

Review updated data of ARNI therapy for HFrEF present at the ESC 2019;
understand the current utilisation of ARNI therapy in HFrEF (guidelines and databases);
interpret potential mechanistic data related to the clinical benefit of ARNI therapy including imaging and biomarker data;
apply new data covering the utilization of ARNI therapy in complex patients including recently decompensated and hospitalized; patients
Apply clinical and real-world evidence data for the treatment HFrEF with ARNI therapy.

Current and Emerging Data on SGLT2 Inhibitors in Heart Failure

Felipe Martinez Scott Solomon Andrew Coats

1.00 EBAC

Published: 02/10/2019

Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data;
differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF);
apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF;
assess the interrelationships linking diabetes, HF and CVD;
interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF. Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.

Heart Failure & Cardiomyopathy: Highlights 2019-2021

lacopo Olivotto

0.25 AMA PRA Category 1 Credit™

Published: 28/07/2021

Recall the efficacy and safety of existing HCM treatments
Summarize results from ongoing trials with experimental treatments for HFrEF and HCM

Heart Failure Management in a Changing Paradigm

1 EBAC

Published: 16/06/2022

Recall the utility of EF in heart failure treatment, patient selection and treatment response
Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
InIncorporate quality of life measures for assessing therapeutic efficacy in HF
Recall outcomes from heart failure trials from recent congress and publications and their impact on practice

Hypertrophic Cardiomyopathy in Review: ESC–HFA 2022 & How to Differentiate HCM From Its Phenocopies

Ahmad Masri

0.50 AMA PRA Credit

Published: 03/08/2022

Recall the efficacy and safety of existing HCM treatments and summarise results from ongoing trials with experimental treatments
Differentiate the signs and symptoms of HCM from other conditions that frequently mask, or mimic the disease and in the presence of comorbidities

Hypertrophic Cardiomyopathy in Review: Highlights 2019-2021

Perry Elliott

0.25 AMA PRA Credit

Published: 22/04/2021

Recall the efficacy and safety of existing HCM treatments
Summarize results from ongoing trials with experimental treatments

Heart Failure

Hypertrophic Cardiomyopathy in Review: ESC–HFA 2022 & How to Differentiate HCM From Its Phenocopies

Ahmad Masri

0.50 AMA PRA Credit

Published: 03/08/2022

Recall the efficacy and safety of existing HCM treatments and summarise results from ongoing trials with experimental treatments
Differentiate the signs and symptoms of HCM from other conditions that frequently mask, or mimic the disease and in the presence of comorbidities

Heart Failure & Cardiomyopathy: Highlights 2019-2021

lacopo Olivotto

0.25 AMA PRA Category 1 Credit™

Published: 28/07/2021

Recall the efficacy and safety of existing HCM treatments
Summarize results from ongoing trials with experimental treatments for HFrEF and HCM

Optimising Treatment of HF

Martin R Cowie Javed Butler Giuseppe Rosano

1.00 (EBAC)

Published: 24/05/2021

Recall recent changes to guidelines following the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes
Describe the type and extent of clinical benefit observed when SGLT2 inhibitors are added to standard HF therapy in patients with HFrEF
Assimilate prevailing hypotheses and insights from key thought leaders on optimal therapeutic sequencing of the ‘five pillars’ of HF therapy
Apply newly gained knowledge on therapeutic sequencing to surrogate patient cases

Current and Emerging Data on SGLT2 Inhibitors in Heart Failure

Felipe Martinez Scott Solomon Andrew Coats

1.00 EBAC

Published: 02/10/2019

Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data;
differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF);
apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF;
assess the interrelationships linking diabetes, HF and CVD;
interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF. Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.

A Review of Emerging ARNI Data in HFrEF

Andrew Coats Scott Solomon Uwe Zeymer

1.00 EBAC

Published: 31/10/2019

Review updated data of ARNI therapy for HFrEF present at the ESC 2019;
understand the current utilisation of ARNI therapy in HFrEF (guidelines and databases);
interpret potential mechanistic data related to the clinical benefit of ARNI therapy including imaging and biomarker data;
apply new data covering the utilization of ARNI therapy in complex patients including recently decompensated and hospitalized; patients
Apply clinical and real-world evidence data for the treatment HFrEF with ARNI therapy.

Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure

David Quek Felipe Martinez

1.00 EBAC

Published: 01/02/2021

Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data.
Differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF).
Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF.
Assess the interrelationships linking diabetes, HF and CVD.
Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.

Heart Failure

Learning objectives

Learning objectives

Learning objectives

Learning objectives

Learning objectives

Learning objectives

Heart Failure

Learning objectives

Learning objectives

Learning objectives

Learning objectives

Learning objectives

Learning objectives

Heart Failure

Learning objectives

Learning objectives

Learning objectives

Learning objectives

Learning objectives

Learning objectives